MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations

Li‑rong Lin1,2†, Xue‑qun Hu1,3†, Li‑hong Lu1,2*, Jia‑zhen Dai1, Ning‑ning Lin1, Re‑hua Wang1,2, Zhang‑xin Xie1,4 and Xue‑mei Chen1,2

Abstract
Familial hypertrophic cardiomyopathy (FHCM) is an autosomal dominant inherited disease caused by mutations in genes encoding cardiac sarcomere proteins. MicroRNAs (miRNAs) play an important role in the pathogenesis of FHCM. In the present study, we aimed to determine the miRNA profile in FHCM patients with myosin-binding protein C3 (MYBPC3) gene mutations. We recruited three FHCM patients and age- and sex-matched controls. The three probands all had hypertrophic obstructive cardiomyopathy with severe myocardial hypertrophy, and two of the three had a history of sudden cardiac death, representing a "malignant" phenotype. We then compared the miRNA expression profiles of three FHCM patients carrying MYBPC3 gene mutations with those of the normal control group using miRNA sequencing technology. Differentially expressed miRNAs were verified using real‑time polymerase chain reaction (qPCR). Target genes and signaling pathways of the identified differentially expressed miRNAs were predicted using bioinformatics analysis. A total of 33 significantly differentially expressed miRNAs were detected in the peripheral blood of the three probands, of which 28 were upregulated, including miR‑208b‑3p, and 5 were downregulated. Real‑time PCR confirmed the upregulated expression of miR‑208b‑3p in FHCM patients (P < 0.05). Bioinformatics analysis showed that miR‑208b‑3p was mainly enriched in 79 target genes including UBE2V2, MED13, YBX1, CNKSR2, GATA4, and SOX5/6, et al. Gene ontology (GO) analysis of target genes showed that miR‑208b was mainly involved in the processes of negative regulation of transcription from RNA polymerase II promoter, and regulation of transcription, DNA templated. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the target genes regulated by miR‑208b‑3p were mainly involved in the Wnt signaling pathway. These findings suggest that FHCM patients with MYBPC3 gene mutations have a specific miRNA expression profile, and that miR‑208b‑3p is significantly upregulated in cardiac hypertrophy. Our results also indicate that miRNA-208b-3p activates the Wnt signaling pathway through its target gene to promote cardiac hypertrophy.

Keywords: Familial hypertrophic cardiomyopathy, MYBPC3, Gene mutation, MicroRNA-sequencing
exhibits significant familial clustering, with offspring having a 50% probability of inheriting the pathogenically mutated gene. To date, more than 1400 pathogenic mutation sites have been identified in more than 25 genes [5]. Common pathogenically mutated genes in Chinese populations include \( \text{MYH7}, \text{MYH6}, \text{MYBPC3}, \text{TNNT2}, \text{TNN3}, \text{TPM1}, \text{ACTC1}, \text{MYL2}, \text{MYL3}, \) and \( \text{LAMP2} [6], \) among which myosin-binding protein C \( (\text{MYBPC3}) \) has the highest mutation rate, accounting for 30–50% of all FHCM cases [7–9]. Studies have shown that more than 70% of \( \text{MYBPC3} \) mutations in FHCM result in truncated cMyBP-C proteins lacking the C-terminus region [10]. For example, one \( \text{MYBPC3} \) mutation results in a truncated peptide that encodes only the N-terminal 258 amino acids and additional, new amino acids [11]. The clinical manifestations of FHCM range from asymptomatic or relatively mild symptoms to heart failure and sudden cardiac death, with FHCM being one of the main causes of sudden cardiac death in adolescents and athletes [12]. However, the clinical phenotypes of FHCM patients with the same gene mutation can vary, and even among the members of the same family, the clinical manifestations, age of onset, and prognosis of patients can also be very different. These findings suggest that there is no direct relationship between gene mutations and clinical phenotypes. These differences are thought to be attributed to different factors including pathogenic genes, environmental cues, and genetic modifiers [13–15].

MicroRNAs (miRNAs) are endogenous non-coding RNAs comprised of approximately 20–25 nucleotides that have regulatory functions. MiRNAs are often considered to be negative regulators of gene expression. MiRNAs can inhibit translation and/or promote mRNA degradation through base pairing with a complementary sequence within the 3′-untranslated region (3′-UTR) of the target gene mRNA transcript. Approximately 60% of protein-coding genes have been found to be regulated by miRNAs at the post-transcriptional level [16–18]. MiRNA sequence screening analysis of many human and animal models of cardiac hypertrophy showed that the expression of some miRNAs (miR-1, miR-133, miR-9, miR-26b, miR-98, miR-181b, and miR-30e) was downregulated, while the expression of other miRNAs (miR-20b, miR-155, miR-199, miR-499, miR-26a, miR-21, miR-23a, and miR-29a) was upregulated. Mechanistically, Ye et al. [19] found that miRNA-20b promotes cardiac hypertrophy by inhibiting mitofusin2-mediated inter-organelle \( \text{Ca}^{2+} \)-cross-talk. Studies have also shown that miR-29a and miR-29c can be used to distinguish between hypertrophic non-obstructive, aortic stenosis, and obstructive cardiomyopathies [20]. Montgomery et al. [21] found that miRNA-208a antagonists improve cardiac function and the survival rate in mice with cardiac hypertrophy. Therefore, identifying miRNA expression profiles in FHCM patients may further our understanding of the pathogenesis of FHCM and offer new therapeutic avenues for treatment.

In the present study, we examined the miRNA expression profiles of FHCM patients carrying \( \text{MYBPC3} \) gene mutations using high-throughput miRNA-seq analysis and used bioinformatic analyses to predict target genes and signaling pathways. The findings of this study provide new insights into the mechanisms underlying FHCM pathogenesis and new perspectives on therapeutic targets.

### Materials and methods

#### Patients

This study protocol was approved by the Ethics Committee of Fujian Provincial Hospital (IRB number: K2017-09-066) and in accordance with the Declaration of Helsinki. All subjects volunteered to participate in this study and provided written informed consent.

Three probands (1 female, 84 years of age, and 2 males, 23 and 65 years of age, respectively) from Han Chinese hypertrophic cardiomyopathy families who were admitted to Fujian Provincial Hospital between October 2017 and October 2018 were recruited as study participants. The clinical diagnostic criteria of HCM were based on the 2014 European Society of Cardiology Guidelines as follows: HCM is defined by a wall thickness ≥ 15 mm in one or more left ventricular (LV) myocardial segments measured by any imaging technique such as echocardiography, cardiac magnetic resonance (CMR), or computed tomography, which could not be explained solely by loading conditions. The clinical diagnosis of HCM in the first-degree relatives of patients with unequivocal disease (left ventricle hypertrophy (LVH) ≥ 15 mm) was based on the presence of an otherwise unexplained increased LV wall thickness ≥ 13 mm in one or more LV myocardial segments, as measured using any cardiac imaging technique (echocardiography, CMR, or CT). Diagnostic criteria for FHCM were based on clinical manifestations and ultrasound diagnosis. In addition to the proband, two or more of the three generations of direct relatives were diagnosed as having HCM or identified as HCM-related sudden death patients. The probands were diagnosed as HCM by two experienced cardiologists based on clinical manifestations, Doppler echocardiography, and electrocardiogram. The control group consisted of sex- and age-matched healthy subjects without cardiac disease. Patients with the following diseases that may cause cardiac hypertrophy were excluded: history of hypertension for over 10 years, rheumatic disease, aortic stenosis, congenital heart disease and metabolic diseases (such as myocardial amyloidosis, Danon disease, and Pompe...
disease), cardiac hypertrophy of athletes, and other organic heart diseases.

Screening and identification of mutation sites in pathogenic genes
Genomic DNA was extracted from peripheral blood (5 ml) collected from patients in the FHCM group. High-throughput micro of common pathogenic genes encoding sarcomere proteins was performed in the Shenzhen Huada Clinical Experimental Center (China) using exon capture technology. The sequenced genes were as follows: beta-myosin heavy chain (MYH7), myosin-binding protein C (MYBPC3), cardiac troponin I and T (TNNI3, TNNT2), tropomyosin alpha-1 chain (TPM1), myosin light chain 3 (MYL3), and cardiac α-actin (ACTC1).

Detection of peripheral blood miRNAs in FHCM patients with gene mutations
Collection of experimental specimens
Venous blood samples (5 ml) were drawn from three FHCM patients and three healthy people to BD Vacutainer Venous Blood Collection Tubes containing EDTA, then turn tubes up and down many times to mixed blood and anticoagulant fully. Centrifuge 3000 rpm at 4 °C for 10 min, collected supernatants as plasma. The fresh plasma samples was frozen immediately at −80 °C until using.

Total RNA isolation
Total RNA from plasma samples were isolated using TRIzol LS Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The concentration and purity of RNA were measured using NanoDropND-1000 (NanoDrop Technologies, USA). The extracted RNA samples were of good quality and high purity, thus meeting the standard requirements for miRNA-seq and RT-qPCR analyses.

MiRNA sequencing
Total RNA from six plasma samples was used to construct miRNA sequencing library. The TruSeq Small RNA library Preparation Kit (Illumina, San Diego, CA, USA) was used for library preparation through the following steps: (1) 3′-adapter ligation; (2) 5′-adapter ligation; (3) cDNA synthesis; (4) PCR amplification; (5) ~ 135 to 155 bp PCR fragments recovery. The libraries were denatured as single DNA strands, captured on Illumina flow cells (Illumina, San Diego, CA, USA), amplified in situ as clusters and finally sequenced for 51 cycles on Illumina NextSeq 500 sequencer. The raw data was analyzed using routine algorithms (KangChen Biotech, Shanghai, China).

RT-qPCR validation of differentially expressed miRNAs
Total RNA samples were reverse-transcribed (RT) to generate cDNA using a stem-loop RT primer (Primer Premier 5.0) with the SuperScript III Reverse Transcriptase kit (Invitrogen) according to the manufacturer's instructions. The RT-qPCR system consisted of 5 μl 2 × Master Mix, 0.5 µl forward primer (10 µM), 0.5 µl reverse primer (10 µM), 2 μl cDNA, and 2 μl double-distilled water. Hsa-miR-423-5p was used as the internal reference. Samples were analyzed in a 96-well plate using a real-time PCR instrument (ViiA 7 Real-time PCR System, Applied Biosystems Technologies, USA). The RT-qPCR conditions were as follows: 95 °C for 10 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 60 s. Melting curves were generated to evaluate reaction specificity under the following conditions: 95 °C for 10 s, 60 °C for 60 s, and 95 °C for 15 s. The stem-loop RT primers showed in Table 1

| miRNA         | Stem-loop RT Primer                                                                 |
|---------------|-------------------------------------------------------------------------------------|
| hsa-miR-2355-5p | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-200c-5p | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-26a-1-3p | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-146b-5p | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-let-7g-3p   | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-103a-3p | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-122-5p  | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-208b-3p | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-377-3p  | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-675-3p  | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
| hsa-miR-423-5p  | 5′GTCGATACCTGCGTTGAGTGAGTGGGCATTTGGAATGCTGATACGATTCGTCGTCAGG3′ |
and PCR primer sequences used in this study are shown in Table 2.

**GO and KEGG pathway analysis**

Gene ontology (GO) project provides a vocabulary to describe gene functions in any organism (http://geneontology.org/), including three domains: biological process, cellular component and molecular function. Fisher’s exact test was used to determine the significance of enriched terms. The lower the $p$ value, the more significant the GO terms (threshold is $p$ value < 0.05).

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis is a functional analysis mapping gene to KEGG pathways [22]. The Fisher’s exact test $p$ value denotes the significance of pathway terms (the $p$ value cutoff is 0.05).

**Statistical analysis**

Differential expression of miRNAs was evaluated using the $p$ value and fold change (FC) value determined using the paired $t$-test, with differentially expressed miRNAs defined as those with a FC in expression (upregulation or downregulation) greater than 1.5 and a $p$ value < 0.05.

TargetScan (http://www.targetscan.org/) and miRDB (http://mirdb.org/miRDB/), which are currently the mainstream databases for predicting target genes of miRNAs, were selected to jointly predict target genes of differentially expressed miRNAs (TargetScan cutoff parameter is total context++ score < −0.05, meanwhile miRdb score > 50). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to identify the function of target genes. Fisher’s exact test was used to determine the significance of enriched terms (the $p$ value cutoff is 0.05). qPCR results were calculated using the $2^{-\Delta\Delta CT}$ method.

**Results**

**Genetic screening of mutated genes in FHCM patients**

High-throughput gene screening was conducted on a total of 16 family members from three FHCM families. Three of the five families had MYBPC3 gene mutations. The clinical data of FHCM probands with MYBPC3 gene mutations are shown in Table 3. Figure 1 showed the echocardiography of FHCM patients, whose left ventricular septal thickness more than 15 mm.

### Table 2  Sequences of PCR primers used in this study

| Gene        | Forward (5′–3′) | Reverse (5′–3′) |
|-------------|----------------|---------------|
| hsa-miR-2355-5p | F:5′GGGCAATCCCCAGATACAAT3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-200c-5p | F:5′GGAGGCCGGCTTACCCAGCGAT3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-26a-1-3p | F:5′GGGGTCTCTATCTGGTACT3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-146b-5p | F:5′GGGGTGAAGACTGAATTCAC3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-let-7g-3p | F:5′GGGGAAATGACGGCCCT3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-103a-3p | F:5′GGGGAGCCAGCATGTCAGG3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-122-5p | F:5′GGGGTGGAGTGTACAAATG3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-208b-3p | F:5′GGGGTCAAGCGAAACAAAAG3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-377-3p | F:5′GGGAATCACAAGGCAAC3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-675-3p | F:5′GAAGCTGTGATGCTCTACC3′ | R:5′GTGCCGTCTGAGTCG3′ |
| hsa-miR-423-5p | F:5′TGAGGGCCAGAGACCA3′ | R:5′GTGCCGTCTGAGTCG3′ |

### Table 3  Clinical data of FHCM probands with the MYBPC3 gene mutations

| Family | Sex | Age | Obstructive | Arrhythmia | NYHA classification | Syncope | Family history of SCD | Maximum wall thickness (mm) | Mutation site | Troponin I (ng/ml) |
|--------|-----|-----|-------------|------------|---------------------|---------|------------------------|-----------------------------|---------------|-------------------|
| Case1  | Male| 65  | Yes         | No         | II                  | Yes     | Yes                    | 10.9                        | c.3369_3370insC | 1.29              |
| Case2  | Male| 23  | Yes         | No         | I                   | No      | Yes                    | 40.5                        | c.3624delIC    | 0.20              |
| Case3  | Female| 84 | Yes         | Atrial fibrillation | III      | No                  | No                   | 33.6                        | c.3624delIC    | 0.31              |
| Ctrl1  | Male| 61  | No          | Yes        | I                   | No      | No                     | 9.8                         | –             | <0.01             |
| Ctrl2  | Male| 23  | No          | Yes        | I                   | No      | No                     | 9.5                         | –             | <0.01             |
| Ctrl3  | Female| 78 | No          | Yes        | I                   | No      | No                     | 10.5                        | –             | <0.01             |

The normal value of Troponin I is <0.1 ng/ml
MiRNA sequencing preliminary screening
A total of 952 miRNAs were detected in our miRNA sequencing analysis of peripheral blood plasma samples from the three FHCM patients with MYBPC3 gene mutations and the three age- and sex-matched healthy controls. Of these, 385 miRNAs were upregulated, 279 were downregulated, and 288 were unchanged in the FHCM patients compared to the control subjects with fold change > 1.5 (Fig. 2a).

Differentially expressed miRNAs
EdgeR was used to analyze the differential miRNA expression between groups. The threshold for screening significantly differentially expressed miRNAs was set at \( p < 0.05 \), with a FC > 1.5. A total of 919 non-significantly differentially expressed miRNAs and 33 significantly differentially expressed miRNAs (28 upregulated and 5 downregulated) were identified in FHCM patients (Fig. 2b). The hierarchical clustering plot shows that the significant differentially expressed miRNAs (Fig. 2c).

RT-qPCR validation of differentially expressed miRNAs
According to previous reports and screening conditions (\( p < 0.05 \) and FC > 1.5) [23], we identified and used RT-qPCR to validate the expression of a total of 10 significantly differentially expressed miRNAs (miR-103a-3p,
miR-122-5p, let-7g-3p, miR-26a-1-3p, miR-675-3p, miR-200c-5p, miR-208b-3p, miR-2355-5p, miR-146b-5p, and miR-377-3p) (Fig. 3a). The expression trends of let-7g-3p, miR-103a-3p, miR-122-5p, miR-146b-5p, miR-26a-1-3p, miR-208b-3p, hsa-miR-675-3p, and hsa-miR-377-3p were consistent with the miRNA-seq analysis, but only miR-208b-3p was significantly different ($p < 0.05$) between the FHCM and control groups. The expression trends of miR-2355-5p and miR-200c-5p obtained by RT-qPCR were not consistent with the miRNA-seq analysis (Fig. 3b).

Prediction of target genes and signaling pathways of miR-208b-3p

Target genes of miR-208b-3p were predicted using the TargetScan and miRDB databases, filtered with TargetScan context++ score $< -0.05$ and miRDB score $> 50$, and the resulting target genes were intersected (Fig. 4a). After removing duplicate genes, a total of 79 target genes were finally obtained (Fig. 4b).

As shown in Fig. 5a, GO analysis of the predicted target genes showed that the target factors of miR-208b-3p were mainly involved in the regulation of transcription from RNA polymerase II promoter, regulation of transcription, protein phosphorylation, etc., processes, mainly localized in nucleoplasm. And their molecular functions were mainly related to protein binding and interactions. KEGG pathway analysis showed that miR-208B-3p was primarily enriched in the Wnt and FoxO signaling pathways, as well as HTLV-1 infection (Fig. 5b), and we added a schematic illustration in Fig. 5c.

Discussion

HCM is a hereditary cardiomyopathy characterized by ventricular asymmetric hypertrophy, with mutations in the MYBPC3 gene detected in 40% of all FHCM cases [24]. Previous studies have shown that, in most cases, HCM with MYBPC3 gene mutations is a late onset
disorder with mild myocardial hypertrophy, a lower rate of sudden cardiac death, and relatively benign disease progression [25, 26]. However, in the present study, echocardiography of the three probands showed that the degree of myocardial hypertrophy was severe (the thickest part of the ventricular wall was > 30 mm) and all were obstructive, and their troponin I increased and had a certain degree of myocardial injury. Among these probands, two families had a history of sudden death. In contrast to other reports [27, 28], our findings indicate that the clinical phenotypes of FHCM with MYBPC3 gene mutations in this study were severe, suggesting that the clinical phenotypes of FHCM in patients with the same gene mutation are variable, and may be affected by many factors including environmental cues, genetic modifiers, and protein post-transcriptional modification.

Previous studies have shown that miRNAs are abundant in the heart and play important roles in a variety of cellular events, such as cell proliferation, apoptosis, autophagy, and cell metabolism. In this study, a total of 952 miRNAs were detected in a miRNA-seq analysis of three cases of FHCM with MYBPC3 gene mutations. Of these 952 miRNAs, 33 differentially expressed miRNAs were identified in the FHCM group, 10 of which were chosen for RT-qPCR validation. We found that miR-208b-3p was the only statistically significant upregulated miRNA, which was consistent with the results of the miRNA-seq analysis. These results suggest that miR-208b-3p expression is upregulated in the peripheral blood of FHCM patients with MYBPC3 gene mutations. Thus, we speculated that miR-208b-3p might be a regulator of cardiac hypertrophy. The miR-208 family is a member of a cardiac-specific group of miRNAs that includes miR-208a and miR-208b. MiR-208a is encoded by an intron of the alpha-cardiac muscle myosin heavy chain gene (Myh6), while miR-208b is encoded by an intron of the beta-cardiac muscle myosin heavy chain gene (Myh7). MiR-208a and miR-208b are expressed in both the left atrium and left ventricle [29], and they share a similar sequence that allows them both to regulate myocardial hypertrophy by targeting Thrap1 and myostatin [30]. In addition, overexpression of miR-208a is sufficient to induce myocardial remodeling by regulating the expression of hypertrophic pathway components [31], indicating that miR-208a plays a pathogenic role in the development of cardiac hypertrophy.

Through bioinformatics analysis, we predicted the target genes of miR-208b-3p and found that miR-208b-3p was mainly enriched in 79 target genes, including UBE2V2, MED13, YBX1, CNKSR2, GATA4, and SOX5/6,
et al. GO analysis revealed that the functions of these 79 target genes involve regulation of regulation of transcription from RNA polymerase II promoter, regulation of transcription, and localized in nucleoplasm and cytoplasm; their molecular functions were mainly related to protein binding and Wnt-activated receptor activity, et al. These predictions illustrate the complex regulatory functions of differentially expressed miRNAs in the pathogenesis of FHCM with MYBPC3 gene mutations. KEGG pathway analysis revealed that miR-208b-3p was mainly enriched in 13 pathways, including the Wnt and FoxO pathway analysis revealed that miR-208b-3p was mainly enriched in 13 pathways, including the Wnt and FoxO signal pathways, as well as HTLV-1 infection, et al. The Wnt signaling pathway includes the canonical Wnt/β-catenin pathway and non-canonical pathways (including the Wnt/calcium pathway and Wnt/planar cell polarity pathway) and is a highly conserved signal transduction pathway. Zhang et al. [32] reported that the Wnt/calcium pathway activates myosin enhancer factor 2 (MEF-2), which plays an important role in cardiac hypertrophy. Wnt5a, another component of Wnt signaling pathway, also induces cardiac hypertrophy by activating the Wnt/PCP pathway [33]. Dawson et al. [34] showed that conditional deletion of beta-catenin inhibited the Wnt/beta-catenin pathway and attenuated hypertrophic responses. The study has shown that overexpression of miR-208b-3p increased the expression levels of Wnt/beta-catenin signaling pathway-related proteins (Wnt3a, Wnt5a and beta-catenin) by suppressing the expression of mediator complex subunit 13(MED13) [35]. Therefore, our findings suggest that miR-208b-3p promotes myocardial hypertrophy by suppressing the activity of its target genes, such as MED13, to activate the Wnt signaling pathway (Fig. 5c).

Limitations
Some limitations of this study should be noted. First, we performed this study with a limited number of patients. Second, we did not study other gene and non-gene mutations associated with FHCM. Therefore, future studies with a larger sample size are required to further investigate the possible associations of miRNAs with FHCM linked to different gene and non-gene mutations. Third, we did not perform any functional assays of miRNA target genes identified in this study. In the study, we found that miRNA-208b-3p is significantly upregulated in FHCM patients. We further uncovered that miRNA-208b-3p potentially activates the Wnt signaling pathway through suppressing the activity of its target genes to promote cardiac hypertrophy.

Conclusion
In the present study, we identified differentially expressed miRNAs in FHCM MYBPC3 gene mutations, and found that miRNA-208b-3p is significantly upregulated in FHCM patients. We further uncovered that miRNA-208b-3p potentially activates the Wnt signaling pathway through suppressing the activity of its target genes to promote cardiac hypertrophy.

Abbreviations
FHCM: Familial hypertrophic cardiomyopathy; miRNA: MicroRNA; MYBPC3: Myosin-binding protein C3; qPCR: Real-time quantitative PCR detecting system; GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; TNNT2: Cardiac troponin T; TNNI3: Cardiac troponin I; TPM1α: Tropomyosin; ACTC: Cardiaca-actin; MYL: Myosin regulatory light chain; CMR: Cardiac magnetic resonance; LVH: Left ventricle hypertrophy; FC: Fold change.

Acknowledgements
We acknowledge the support of the Fujian Institute of Medical Sciences.

Author contributions
LL contributed to the design and performance of this study; LL and XH contributed to the data analysis and writing of the manuscript; JD and NL conducted the RT-PCR; LL and RW contributed to the acquisition of resources; ZK and XC contributed to the data analysis. All authors approved the final manuscript.

Funding
This work was supported by grants from the Fujian Natural Science Foundation 2019 (Grant No. 2019J01168) and Sponsored by Fujian Provincial Health Technology Project (Grant No. 2019‑CX‑11), and Startup Fund for Scientific Research by Fujian Medical University 2018 (Grant No. 2018QH1158).

Data availability
The datasets used and/or analyzed in the present study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Fujian Provincial Hospital (Approval No. K2018-06-027) and was conducted in accordance with the Declaration of Helsinki. All subjects volunteered to participate in this study and provided written informed consent.

Consent for publication
Not applicable in the declarations section.

Competing interests
The authors declare that they have no competing interests.

Author details
1Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China. 2Department of Cardiology, Fujian Provincial Hospital, Fuzhou 350001, China. 3Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China. 4Department of Emergency, Fujian Provincial Hospital, Fuzhou 350001, China.

Received: 29 April 2021   Accepted: 8 June 2022
Published online: 18 June 2022

References
1. Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899–908.
2. Brito D, Miltenberger-Miltenyi G, Vale Pereira S, Silva D, Diogo AN, Madeira H. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev Port Cardiol. 2012;31:577–67.
3. Kassem H, Azer RS, Saber-Ayad M, Moharem-Elgamal S, Magdy G, Elgindy A, et al. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. J Cardiovasc Transl Res. 2013;6(6):55–80.

4. Lopes JS, Zekavati A, Syrnis P, Hubank M, Giambartolomei C, Dalageorgou C, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet. 2013;50:228–39.

5. Ji F, Liu Q, Feng Z, Han X, Li Z. Genetic association between 1425G/A SNP in PRKCH and hypertrophic cardiomyopathy in a Chinese population. Oncotarget. 2017;8:14839–44.

6. Wang X, Zhou H, Hua Y, Li Y. Approaching the facts between genetic mutation and clinical practice of hypertrophic cardiomyopathy: a case report with RAF1 770C>T mutant. Medicine (Baltimore). 2016;95:e4815.

7. Kaski JP, Syrnis P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2:436–41.

8. Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53:261–7.

9. Brough J, Jain M, Jerves T, Kruszka P, McGuffey E. Genetic screening for hypertrophic cardiomyopathy in large, asymptomatic military cohorts. Am J Med Genet. 2010;152A:11–5.

10. Barefield D, Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol. 2010;48:866–75.

11. Carrier L, Bonne G, Bärend A, Yu B, Richard P, Nief F, et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res. 1997;80:427–34.

12. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.

13. Carstens N, van der Merwe L, Revera M, Heradien M, Goosen A, Brink PA, et al. Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure. J Renin Angiotensin Aldosterone Syst. 2011;12:274–80.

14. Friedrich FW, Bausero P, Sun Y, Treszl A, Krämer E, Juh D, et al. A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J. 2009;30:1648–55.

15. Sabater-Molina M, Pérez-Sánchez I, Hernández Del Rincón JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: a review of current state. Clin Genet. 2018;93:3–14.

16. Forman JJ, Coller HA. The code within the code: microRNAs target coding and non-coding RNAs. Nat Rev Mol Cell Biol. 2012;13:986–93.

17. Catalonotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17:1712.

18. Qiu Y, Cheng R, Liang C, Yao Y, Zhang W, Zhang J, et al. MicroRNA-20b promotes cardiac hypertrophy by the inhibition of Mitofusin 2-mediated inter-organelle Ca(2+)/cross-talk. Mol Ther Nucleic Acids. 2020;19:1343–56.

19. Derda AA, Thurm S, Lorenzen JM, Bayevdziek U, Heineke J, Keyser B, et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. 2015;196:115–22.

20. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124:1537–47.

21. Kaneshia M, et al. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–d551.

22. Wang X, Zhou H, Hua Y, Li Y. Approaching the facts between genetic mutation and clinical practice of hypertrophic cardiomyopathy: a case report with RAF1 770C>T mutant. Medicine (Baltimore). 2016;95:e4815.

23. Yang X, Chen H, Chen Y, Birnbaum Y, Liang R, Ye Y, et al. Circulating miRNA expression profiling and target prediction in patients receiving dexmedetomidine. Cell Physiol Biochem. 2018;50:552–68.

24. Richard P, Charron P, Carrier L, Ledieu C, Cheav T, Pichereau C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227–32.

25. Nimiru H, Bachinski LL, Sangwatanaorat S, Watkins H, Chudley AE, McKenna W, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–57.

26. Charron P, Dubourg O, Desnos M, Bennaoucer M, Carrier L, CamproUX AC, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998;97:2230–6.

27. Wang S, Zou Y, Fu C, Xu X, Wang J, Song L, et al. Worse prognosis with gene mutations of beta-myosin heavy chain than myosin-binding protein C in Chinese patients with hypertrophic cardiomyopathy. Clin Cardiol. 2008;31:114–8.

28. Maniglia JD, Credidio FL, de Oliveira TG, Reis RF, Antunes Mde O, de Araujo AGQ, et al. Screening of MVH, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy. Am Heart J. 2013;166:775–82.

29. Kakimoto Y, Tanaka M, Kamiguchi H, Hayashi H, Ochiai E, Osawa M. MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart. Int J Cardiol. 2016;211:43–8.

30. Calkas TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZF, et al. MicroRNA-20a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Investig. 2009;119:2772–86.

31. Wang BW, Wu GJ, Cheng WP, Shyu KG. MicroRNA-20a8 increases myocardial fibrosis via endoglolin in volume overloading heart. PLOS ONE. 2014;9:e84188.

32. Zhang M, Hagenmüller M, Riffel JH, Kreusser MA, Bernholdt E, Fan J, et al. Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates diseased-induced cardiomyopathy. Hypertension. 2015;65:335–44.

33. Hagenmüller M, Riffel JH, Bernholdt E, Fan J, Katus HA, Hardt SE. Dapper-1 is essential for Wnt5a induced cardiomyocyte hypertrophy by regulating the Wnt/PCP pathway. FEBS Lett. 2014;588:2230–7.

34. Dawson K, Aflaki M, Nattel S. Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. J Physiol. 2013;591:1409–32.

35. Wang Z, Yang Y, Xiong W, et al. Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signalin—pathway axis. Biomed Pharmacother. 2020;125:110001.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.